A 3,8-disubstituted adenine derivative, preparation method and application thereof
By preparing 3,8-disubstituted adenine derivatives, the problem of insufficient types of PDE8 inhibitors was solved, realizing effective inhibition and therapeutic potential of PDE8, and exhibiting good liver microsomal stability and pharmacokinetic properties.
Patent Information
- Application Number
- CN202410296480.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-15
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-03-15
AI Technical Summary
There are few types of PDE8 inhibitors in the current technology, making it difficult to effectively explore their physiological effects. There is a lack of inhibitors with strong activity, high selectivity, and excellent properties.
A 3,8-disubstituted adenine derivative is provided, and the compound is prepared by a specific synthetic route, including reaction steps using liquid bromine, basic reagents and haloalkanes, to synthesize a PDE8 inhibitor with a novel structure.
The compound exhibits good inhibitory activity against PDE8, with high selectivity, good liver microsomal stability, and excellent oral pharmacokinetic properties, making it suitable for the treatment of PDE8-related diseases.
Smart Images

Figure BDA0004742367060000021 
Figure BDA0004742367060000031 
Figure BDA0004742367060000041
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of pharmaceutical chemistry, and more specifically, relates to a 3,8-disubstituted adenine derivative, a preparation method and an application thereof. Background Art
[0002] Phosphodiesterase (PDE) is the only super enzyme family in the body that is responsible for the specific hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). It catalyzes the hydrolysis of 3′-phosphate bonds to generate 5′-AMP and 5′-GMP, respectively. cAMP and cGMP are important second messengers in cells, regulating a variety of signaling pathways, such as various intracellular physiological processes and neurobehavioral functions, through direct interactions with cAMP-dependent protein kinase A (PKA) and cGMP-dependent protein kinase G (PKG), respectively. To date, nearly twenty PDE inhibitors have been approved for marketing in various countries, such as the PDE5 inhibitor sildenafil and the PDE4 inhibitor apremilast. cAMP-specific PDE subtypes include PDE4, PDE7 and PDE8. Among them, PDE8 has the highest affinity for cAMP substrates among all PDEs, with a Km value of 40-150nM, which is more than 40 times that of PDE4.
[0003] The biological function of PDE8 has not been thoroughly studied yet, but judging from its expression level, it is speculated that PDE8 has important physiological effects in different life processes, especially on the functions of the brain and thyroid gland, so it is likely to be a suitable therapeutic target for central nervous system diseases. Studies have shown that the spatial memory and motor coordination abilities of PDE8B knockout mice are enhanced, and the level of PDE8 in the brains of aged rats is overexpressed. These phenomena indicate that inhibiting PDE8 may enhance cognitive function, prevent age-induced motor coordination decline, and treat age-related diseases.
[0004] However, the prior art has little research on PDE8, and no inhibitor with good effect has been found for clinical application of PDE8. There are only a few studies on PDE8 inhibitors. For example, patent No.: WO2011058478A1 discloses "a substituted triazolopyrimidine inhibitor of PDE8 enzyme". This type of inhibitor has different degrees of inhibitory activity on PDE8 enzyme, but its clinical effect is still unknown, and it is impossible to explore the physiological effects of PDE8. Therefore, it is urgent to find PDE8 inhibitors with strong activity, high selectivity and excellent properties to explore the physiological effects of PDE8. Summary of the invention
[0005] The technical problem to be solved by the present invention is to overcome the small number of PDE8 inhibitors available in the prior art. To this end, the present invention provides a 3,8-disubstituted adenine derivative, which is a class of compounds with novel structures and good inhibitory effects on the activity of phosphodiesterase type 8, and can be used in the prevention or treatment of diseases related to phosphodiesterase type 8 metabolism.
[0006] The above-mentioned purpose of the present invention is achieved through the following technical solutions:
[0007] The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof,
[0008]
[0009] in:
[0010] R1, R2 and R3 are each independently selected from hydrogen, halogen, substituted or unsubstituted C 1-6 One of the alkoxy groups;
[0011] R4 is selected from hydrogen, halogen or
[0012] R5 is hydrogen, substituted or unsubstituted C 1-6 alkyl.
[0013] Further, R1 and R3 are each independently selected from hydrogen or halogen; R2 is selected from halogen, substituted or unsubstituted C 1-6 One of the alkoxy groups.
[0014] Furthermore, the R1, R2 or R3 is C 1-6 Alkoxy, and C 1-6 At least one H on the alkoxy group is substituted by a halogen atom.
[0015] Further, the R5 is C 1-6 Alkyl, and C 1-6 At least one H on the alkyl group is replaced by a halogen atom, C 4-5 Heteroaryl, halogenated C 4-5 Heteroaryl, C6 aryl, halogenated C6 aryl, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl or tetrahydropyran substitution.
[0016] Furthermore, the substituted or unsubstituted C 1-6 The alkoxy groups are each selected from one of -OCH3, -OCH2CH3, -OCH(CH3)2, -OCH2CH2CH3, -OCHF2, -OCH2CHF2, and -OCH2CH2CF3.
[0017] Furthermore, the substituted or unsubstituted C1-6 The alkyl groups are selected from -CH3, -CH2CH3, -CH(CH3)2, -CH2CH2CH3, -CH2CH(CH3)2, -CH2CHF2, One of them.
[0018] Furthermore, the pharmaceutically acceptable salt is a salt product obtained by reacting the compound of formula (I) with an acid, wherein the acid includes one or more of hydrochloric acid, hydrobromic acid, hydrofluoric acid, phosphoric acid, acetic acid, oxalic acid, sulfuric acid, methanesulfonic acid, salicylic acid, trifluoroacetic acid, trifluoromethanesulfonic acid, naphthalenesulfonic acid, maleic acid, fumaric acid, citric acid, tartaric acid, succinic acid, malic acid and glutamic acid.
[0019] Furthermore, the structure of the compound represented by formula (I) is shown as one of the following:
[0020]
[0021]
[0022] The present invention also provides a pharmaceutical composition, which comprises: the compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0023] In addition, the present invention also provides a method for preparing the compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The synthetic route of the compound represented by formula (I) is as follows:
[0024]
[0025] The specific steps include:
[0026] (I) When X in compound 1 is H:
[0027] (1) Compound 1 is dissolved in a solvent, and reacted at 0-60° C. for 12-18 hours under the action of liquid bromine, and compound 2 is obtained after the reaction is complete;
[0028] (2) dissolving the compound 2 obtained in step (1) in a solvent, reacting with a halogenated hydrocarbon at 0-60° C. for 8-16 h in the presence of an alkaline reagent, and obtaining compound 3 after the reaction is complete;
[0029] (3) dissolving the compound 3 obtained in step (2) in a solvent, reacting at 100-150° C. for 20-36 hours under the action of thiourea, and generating compound 4 after the reaction is complete;
[0030] (4) dissolving the compound 4 obtained in step (3) in a solvent, reacting with a halogenated hydrocarbon at 60-120° C. for 8-16 h in the presence of an alkaline reagent, and obtaining a compound represented by formula (I) after the reaction is complete;
[0031] (ii) When X in compound 1 is SH:
[0032] (1) Compound 1 is dissolved in a solvent and reacted with a halogenated hydrocarbon or a p-toluenesulfonate derivative at 80-150° C. for 8-16 hours in the presence of an alkaline reagent. After the reaction is complete, compound 5 is obtained;
[0033] (2) Compound 5 is dissolved in a solvent, and reacted with a halogenated hydrocarbon at 0-60° C. for 8-16 hours under the action of an alkaline reagent, to obtain a compound represented by formula (I) after the reaction is complete;
[0034] Wherein, the solvent involved in the above steps is one or more of water, N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, N-methylpyrrolidone, methanol, ethanol, isopropanol, acetonitrile, acetone, tetrahydrofuran, chloroform, ethyl acetate, dichloromethane, 1,2-dichloroethane, and 1,4-dioxane;
[0035] The alkaline reagent involved in the above steps is selected from one or more of diisopropylethylamine, triethylamine, 4-dimethylaminopyridine, piperidine, sodium bicarbonate, sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, potassium tert-butoxide, sodium hydride, sodium methoxide, and sodium ethoxide.
[0036] The present invention also provides an application of a substance X in the preparation of a phosphodiesterase type 8 inhibitor, wherein the substance X is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof or the pharmaceutical composition.
[0037] The present invention also provides an application of a substance X in the preparation of a drug, wherein the substance X is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof or the pharmaceutical composition; the drug is a drug for treating and / or preventing diseases associated with phosphodiesterase type 8.
[0038] The present invention has the following beneficial effects:
[0039] The 3,8-disubstituted adenine derivative provided by the present invention has a good inhibitory effect on phosphodiesterase type 8, has high selectivity for other phosphodiesterase subtypes, and also has good liver microsomal stability and oral pharmacokinetic properties. It can be used in the preparation of drugs for treating and / or preventing diseases related to phosphodiesterase type 8, has good development potential, and increases the range of options for drugs for treating phosphodiesterase type 8 related diseases. DETAILED DESCRIPTION
[0040] The present invention is further described below in conjunction with specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. Unless otherwise specified, the reagents and materials used in the following examples are commercially available.
[0041] The preparation method of the 3,8-disubstituted adenine derivative (I) provided by the present invention is as follows:
[0042]
[0043] The specific steps include:
[0044] (I) When X in compound 1 is H:
[0045] (1) Compound 1 is dissolved in N,N-dimethylformamide, and the reaction is completed under the action of liquid bromine to obtain Compound 2;
[0046] (2) dissolving the compound 2 obtained in step (1) in N,N-dimethylacetamide, and reacting it with a halogenated hydrocarbon under the action of diisopropylethylamine to obtain a compound 3;
[0047] (3) dissolving the compound 3 obtained in step (2) in N,N-dimethylformamide, and reacting completely under the action of thiourea to generate compound 4;
[0048] (4) dissolving the compound 4 obtained in step (3) in methanol, and reacting it completely with a halogenated hydrocarbon under the action of triethylamine to obtain a compound represented by formula (I);
[0049] (ii) When X in compound 1 is SH:
[0050] (1) Compound 1 is dissolved in water and reacts completely with a halogenated hydrocarbon or a p-toluenesulfonate derivative under the action of 4-dimethylaminopyridine to obtain compound 5;
[0051] (2) Compound 5 is dissolved in acetonitrile and reacted with a halogenated hydrocarbon under the action of piperidine to obtain a compound represented by formula (I). The synthesis process of 3,8-disubstituted adenine derivatives and the effect verification are described below.
[0052] Example 1: Synthesis of Compounds 1a-n
[0053] (1) Synthesis of intermediate 8-bromo-9H-purin-6-amine (M1)
[0054] Adenine (16 mmol) was dissolved in water (200 mL), and liquid bromine (6 mL) was slowly added dropwise. The mixture was reacted at room temperature for 16 hours. The mixture was filtered, and the residual bromine water was washed off with water, and dried to obtain a yellow solid. The yield was 28%.1 H NMR(400MHz, DMSO-d6)δ8.23(s,1H),8.06(s,2H).ESI:calculated for C5H4BrN5=211.96,213.96.Observed m / z[MH] - =212.00,214.00.
[0055] (2) Synthesis of intermediate 3-benzyl-8-bromo-3H-purin-6-amine (M2)
[0056] Dissolve the intermediate M1 (10 mmol) in N, N-dimethylformamide (15 mL), add potassium carbonate (20 mmol), and then drop benzyl bromide (10 mmol) and react at room temperature overnight. Dilute the reaction system with water and extract three times with ethyl acetate. Collect the organic layer, wash three times with saturated brine, and dry over anhydrous sodium sulfate. Remove the solvent by vacuum rotary evaporation and purify by column to obtain a white solid. Yield 33%. 1 HNMR (400MHz, DMSO-d6) δ8.54(s,1H),8.20(s,1H),8.08(s,1H),7.42–7.28(m,5H),5.47(s,2H).
[0057] (3) Synthesis of intermediate 6-amino-3-benzyl-3H-purine-8-thiol (M3)
[0058] Dissolve the intermediate M2 (3 mmol) in n-butanol (15 mL), add thiourea (24 mmol), and reflux for 24 hours. After the reaction is complete, dilute with water, filter, and wash the residue with water. Dry to obtain a white solid. The yield is 86%. 1 HNMR (400MHz, DMSO-d6) δ11.39(s,1H),8.51(s,1H),7.47–7.26(m,5H),5.42(s,2H).
[0059] (4) Synthesis of final products 1a-n
[0060] The intermediate M3 (0.3 mmol) and potassium hydroxide (0.45 mmol) were dissolved in a mixed solution of ethanol and water (2:1, 3 mL), and iodomethane or alkyl bromide or arylmethyl bromide (0.36 mmol) were added, and the reaction was continued at 80°C overnight. After the reaction was complete, the mixture was diluted with water and extracted with ethyl acetate three times. The organic layers were combined, dried, the solvent was evaporated, and purified by column to obtain a white solid. The results are shown in Table 1.
[0061] Table 1
[0062]
[0063]
[0064]
[0065] Example 2: Synthesis of Compound 2a-1
[0066] (1) Synthesis of intermediate 5-nitropyrimidine-4,6-diamine (M4)
[0067] Dissolve 4,6-dichloro-5-nitropyrimidine (26 mmol) in aqueous ammonia (15 mL) and react at 60°C for 5 hours. Filter by suction, wash with water, and dry the residue to obtain a white solid. The yield is 95%. 1 H NMR (400MHz, DMSO-d6) δ8.49(s,2H),8.41(s,2H),7.88(s,1H).
[0068] (2) Synthesis of intermediate pyrimidine-4,5,6-triamine (M5)
[0069] Dissolve the intermediate M4 (20 mmol) in ethanol (400 mL), add Raney nickel (5 g), dropwise add 80% hydrazine hydrate solution (8 mL), react at room temperature for 40 hours, filter, evaporate the solvent, and dry to obtain a white solid. Yield: 93%. 1 HNMR (400MHz, DMSO-d6) δ7.45(s,1H),5.55(s,4H),3.76(s,2H).
[0070] (3) Synthesis of intermediate 6-amino-9H-purine-8-thiol (M6)
[0071] Mix the intermediate M5 (10 mmol) and thiourea (35 mmol), heat to 180°C and react for 1 hour. Add water while hot, crush the solid, and stir at room temperature overnight. Filter by suction, wash with saturated brine, and dry the residue to obtain a yellow solid. Yield: 73%. 1 HNMR (400MHz, DMSO-d6) δ7.45(s,1H),5.55(s,4H),3.76(s,2H).
[0072] (4) Synthesis of intermediates M7a-e
[0073] Dissolve the intermediate M6 (1 mmol) and potassium hydroxide (2 mmol) in a mixed solution of ethanol and water (2:1, 3 mL), add bromide or p-toluenesulfonate derivative (1.5 mmol), and react at room temperature overnight. After the reaction is complete, remove the ethanol by rotary evaporation, and adjust the pH to 5 with glacial acetic acid. Filter by suction, wash with water, and dry the filter residue to obtain a yellow or white solid.
[0074] 8-(propylthio)-9H-purin-6-amine(M7a), yield 74%. 1 H NMR (400MHz, DMSO-d6) δ12.95(s,1H),8.02(s,1H),6.96(s,2H),3.24–3.18(m,2H),1.73–1.64(m,2H),0.98(t,J=7.3Hz,3H).
[0075] The yield of 8-((2-(tetrahydro-2H-pyran-4-yl)ethyl)thio)-9H-purin-6-amine (M7b) was 54%. 1 H NMR(500MHz,DMSO-d6)δ12.98(s,1H),8.02(s,1H),7.00(s,2H),3.82(dd,J =11.0,3.6Hz,2H),3.32–3.20(m,4H),1.68–1.55(m,5H),1.24–1.10(m,2H).
[0076] The yield of 8-(((4,4-difluorocyclohexyl)methyl)thio)-9H-purin-6-amine (M7c) was 55%. 1 H NMR (400MHz, DMSO-d6) δ12.96(s,1H),8.05(s,1H),6.98(s,2H),3.25(d,J=6.7Hz ,2H),2.05–1.96(m,2H),1.92–1.87(m,2H),1.85–1.70(m,3H),1.33–1.23(m,2H).
[0077] The yield of 8-(((tetrahydro-2H-pyran-4-yl)methyl)thio)-9H-purin-6-amine (M7d) was 49%. 1H NMR (400MHz, DMSO-d6) δ12.88(s,1H),8.04(s,1H),6.94(s,2H),3.84(dd,J=11.2,3. 0Hz,2H),3.27–3.20(m,4H),1.88–1.77(m,1H),1.75–1.64(m,2H),1.34–1.17(m,2H).
[0078] 8-((cyclohexylmethyl)thio)-9H-purin-6-amine(M7e), yield 38%. 1 H NMR (400MHz, DMSO-d6) δ12.82(s,1H),8.04(s,1H),6.96(s,2H),3.18(d,J=6.8Hz,2H),1.82( d,J=11.3Hz,2H),1.73–1.64(m,2H),1.62–1.48(m,2H),1.27–1.09(m,3H),1.07–0.92(m,2H).
[0079] (5) Synthesis of Final Product 2a-1
[0080] The intermediate M7a-e (0.5 mmol) was dissolved in N, N-dimethylformamide (1 mL), cesium carbonate (1 mmol) was added, and then a benzyl bromide derivative (0.5 mmol) was added, and the reaction was allowed to proceed overnight at room temperature. After the reaction was complete, the mixture was diluted with water and extracted three times with ethyl acetate. The organic layers were combined, washed three times with brine, dried, and the solvent was evaporated by rotary evaporation. The mixture was purified by column chromatography to obtain a white or light yellow solid. The results are shown in Table 2.
[0081] Table 2
[0082]
[0083]
[0084]
[0085] Example 3: Synthesis of Compounds 3a-f
[0086] The synthesis process of compounds 3a-f refers to the synthesis process of compounds 2a-1 in the above Example 2, and the results are shown in Table 3.
[0087] Table 3
[0088]
[0089]
[0090]
[0091] Example 4: Synthesis of compound 3-(3,5-dichloro-4-(2,2-difluoroethoxy)benzyl)-3H-purin-6-amine (4a)
[0092] (1) Synthesis of intermediate N-(2,4-dimethoxybenzyl)-9H-purin-6-amine (M8)
[0093] Dissolve 6-chloropurine (20 mmol), 2,4-dimethoxybenzylamine (24 mmol) and N,N-diisopropylethylamine (40 mmol) in n-butanol (16 mL) and react at 100°C for 3 h. A white solid precipitates, cools to room temperature, adds acetonitrile to dilute, filters, and washes to obtain a white solid. The yield is 96%. 1 HNMR(400MHz,DMSO-d6)δ12.92(s,1H),8.12(d,J=19.2Hz,2H),7.76(s,1H),7.07( s,1H),6.56(s,1H),6.42(d,J=7.8Hz,1H),4.59(s,2H),3.82(s,3H),3.72(s,3H).
[0094] (2) Synthesis of the intermediate 3-(3,5-dichloro-4-(2,2-difluoroethoxy)benzyl)-N-(2,4-dimethyl-benzyl)-3H-purin-6-amine (M9)
[0095] Intermediate M8 (7 mmol) and 5-bromomethyl-1,3-dichloro-2-(2,2-difluoroethoxy)benzene (7 mmol) were dissolved in N,N-dimethylformamide (40 mL) and reacted at 110°C overnight. The solvent was dried using an oil pump, and the mixed solution of dichloromethane and methanol was slurried, filtered, and washed to obtain a white solid. The yield was 74%. 1 H NMR (400MHz, CDCl3) δ8.07(s,1H),7.99(s,1H),7.38(s,2H),7.26–7.22(m,1H),6.47(d,J=1.9Hz,1H),6.41(dd,J=8.2,1. 9Hz, 1H), 6.14 (tt, J = 55.2, 4.4Hz, 1H), 5.45 (s, 2H), 4.80 (s, 2H), 4.21 (td, J = 12.9, 4.2Hz, 2H), 3.85 (s, 3H), 3.79 (s, 3H).
[0096] (5) Synthesis of the final product 3-(3,5-dichloro-4-(2,2-difluoroethoxy)benzyl)-3H-purin-6-amine (4a)
[0097]
[0098] Intermediate M9 (5 mmol) was dissolved in a trifluoroacetic acid / dichloromethane mixed solution (1:3, 20 mL) and reacted at room temperature overnight. The solvent was evaporated, diluted with methanol, and the pH was adjusted to 8 with ammonia methanol. The product was purified by column chromatography to obtain a white solid with a yield of 97%. 1 H NMR (400MHz, MeOD) δ 8.56 (s, 1H), 8.08 (s, 1H), 7.53 (s, 2H), 6.19 (tt, J = 54.6, 4.2Hz, 1H), 5.54 (s, 2H), 4.23 (td, J = 13.6, 2.7Hz, 2H).
[0099] Example 5: Synthesis of compound 8-bromo-3-(3,5-dichloro-4-(2,2-difluoroethoxy)benzyl)-3H-purin-6-amine (4b)
[0100]
[0101] Compound 4a (1 mmol) in Example 4 was dissolved in anhydrous N,N-dimethylformamide (2.5 mL), and N-bromosuccinimide (1.2 mmol) was added, and the mixture was reacted at room temperature overnight. The solvent was dried using an oil pump, and the mixture was purified by column chromatography to obtain a white solid. The yield was 83%. 1 H NMR (500MHz, Acetone-d6) δ8.52 (s, 1H), 7.69 (s, 2H), 6.33 (tt, J = 54.7, 3.8 Hz, 1H), 5.57 (s, 2H), 4.33 (td, J = 13.9, 3.9 Hz, 2H).
[0102] Effect Example 1: Biological Activity Assay
[0103] (1) Determination of the inhibitory activity of compounds on PDE8A enzyme
[0104] 3H-cAMP was diluted to 20,000-30,000 cpm with assay buffer (20 mM Tris-HCl (pH 7.5), 10 mM MnCl2 and 1 mM DTT). The substrate, PDE8A protein and the test compound were incubated at room temperature for 15 minutes, and then 0.2 M ZnSO4 and 0.2 M Ba(OH)2 were added to terminate the reaction. The unreacted cAMP in the supernatant was measured using a PerkinElmer 2910 counter. 3 H-cAMP. IC of each tested compound 50 The calculation used 8-10 different concentrations and the test was repeated 3 times. The activity results are shown in Table 4.
[0105] Table 4 Inhibitory activity of compounds on PDE8A enzyme
[0106] Compound <![CDATA[PDE8A,IC 50 (nM)]]> Compound <![CDATA[PDE8A,IC 50 (nM)]]> Compound <![CDATA[PDE8A,IC 50 (nM)]]> 1a 18461±277 1m 1084±207 2k 452±87 1b 7711±1065 1n 2259±81 2l 1527±304 1c 13674±361 2a >1000 3a 900±207 1d 2592±55 2b >1000 3b 459±30 1e 2967±16 2c >1000 3c 77±13 1f 4964±383 2d >1000 3d 102±17 1g 1868±150 2e >1000 3e 228±49 1h 473±70 2f >1000 3f 31±4 1i 1912±172 2g >1000 4a 634±173 1j 9615±1355 2h 2556±586 4b 17±3 1k 4833±1152 2i >1000 1l 5207±832 2j >1000
[0107] (2) Selectivity test of compound 4b against other PDE subtypes
[0108] Compound 4b was used as a representative to test its selectivity index for the PDEs family. The test method was the same as the above-mentioned determination of the PDE8A enzyme inhibitory activity. The test results are shown in Table 5. From the data in the table, it can be seen that compound 4b has good sub-selectivity for other PDEs.
[0109] Table 5 Selectivity of compound 4b for other PDE subtypes
[0110] PDE subtypes <![CDATA[IC 50 (nM)]]> Selectivity Index PDE8A 17±3 - PDE1C >10000 >588 PDE2A >10000 >588 PDE3A ~10000 ~588 PDE4D ~10000 ~588 PDE9A >10000 >588
[0111] Effect Example 2: Determination of metabolic stability of compound 4b in rat liver microsomes
[0112] This experiment used the method of incubating compound 4b with liver microsomes in vitro and determining the percentage of the remaining compound by LC-MS / MS to study the metabolic stability of compound 4b in liver microsomes. The specific steps are as follows:
[0113] (I) Solution preparation
[0114] (1) Preparation of Tris / HCl (0.1 M, pH 7.4) buffer: Weigh 12.12 g of TRIS (tris-hydroxymethylaminomethane), dissolve it in 800 mL of water, adjust the pH to 7.4 with HCl (2 M), and then make up to 1000 mL with water.
[0115] (2) Preparation of MgCl2: Prepare MgCl2 (100 mM) solution using 0.1 M Tris / HCl buffer, divide into aliquots and store at -20°C.
[0116] (3) Preparation of NADPH: Prepare NADPH (10 mM) solution with 0.1 M Tris / HCl buffer, divide into portions and store at -20°C.
[0117] (4) Preparation of test compounds: Dissolve the compound in DMSO to obtain a stock solution with a concentration of 10 mM. Dilute to 1 mM with DMSO and then dilute with 0.1% BSA-water to obtain a working solution with a concentration of 2 μM. In the incubation system, the 2 μM working solution is diluted 20 times to a final concentration of 0.1 μM. The DMSO concentration in the incubation system is ≤ 0.01%.
[0118] (5) Preparation of positive control compound: Dilute 2 mM VIVID stock solution 50 times with 2 μM test substance working solution. The final concentration of VIVID in the incubation system is 2 μM.
[0119] (II) Experimental methods
[0120] Liver microsomes were incubated in 96-well plates. The volume of each incubation system was 450 μL. The medium was 0.1M Tris buffer (pH 7.4), including liver microsomes with a final concentration of 0.33 mg / mL, 0.1 μM of the test drug, 5.0 mM MgCl2, 0.01% DMSO, 0.005% BSA and 1.0 mM NADPH. Incubation was performed at 37°C. NADPH was added after pre-incubation for 10 minutes to initiate the reaction. 50 μL was taken from the incubation system after 0, 7, 17, 30, and 60 minutes, and the same volume of methanol was added to terminate the reaction. The results are shown in Table 6 below.
[0121] Table 6 Metabolic stability of compound 4b in rat liver microsomes
[0122] Compound Hepatic microsome half-life time (min) 4b 169
[0123] Effect Example 3: In vivo pharmacokinetic determination of compound 4b
[0124] The time course of blood drug concentration of compound 4b was observed after oral gavage and intravenous injection to rats, and the corresponding pharmacokinetic parameters and absolute bioavailability were estimated. The determination process and results were as follows:
[0125] (1) Measurement process
[0126] Six rats were divided into two groups, and compound 4b was administered by gavage and tail vein injection, respectively. The intravenous injection group was injected 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, and 24h after administration; the gavage group was injected 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, and 24h after administration. About 0.25mL of blood samples were collected from the jugular vein. The concentration of LWWX22194 in rat plasma samples was determined by LC-MS / MS, and the PK parameters of each compound were statistically analyzed and calculated (WinNonlin V5.2, Pharsight), reflecting the pharmacokinetic properties of the compounds of the present invention in rats.
[0127] (2) Measurement results
[0128] After a single intravenous injection of 2.5 mg / kg of compound 4b in rats, the main pharmacokinetic parameters of intravenous administration were: Cmax was 1847 ng / mL, Tmax was 0.083 h, T1 / 2 was 3.78 h, AUC0-T was 4900 hr*ng / mL, AUC0-∞ was 5028 hr*ng / mL, Vz was 2820 mL / kg, Cl was 512 mL / hr / kg, MRT0-t was 3.104 h, MRT0-∞ was 3.53 h. The results are shown in Table 7 below.
[0129] Table 7 Pharmacokinetic parameters of 4b in rats after intravenous injection (n=3)
[0130] Parameter Units No.1 No.2 No.3 Mean SD T1 / 2 hr 2.12 5.11 4.12 3.78 1.52 Tmax hr 0.083 0.083 0.083 0.083 0.000 Cmax ng / ml 2170 1600 1770 1847 293 C0 ng / ml 2543 1615 1910 2023 474 <![CDATA[AUC 0-t ]]> hr*ng / ml 4480 4054 6167 4900 1117 <![CDATA[AUC 0-∞ ]]> hr*ng / ml 4712 4128 6245 5028 1094 V ml / kg 1620 4463 2378 2820 1472 Cl ml / hr / kg 531 606 400 512 104 <![CDATA[MRT 0-t ]]> hr 1.93 3.25 4.14 3.10 1.11 <![CDATA[MRT 0-∞ ]]> hr 2.38 3.75 4.46 3.53 1.06
[0131] After oral administration of 10 mg / kg 4b to rats, the main pharmacokinetic parameters of oral administration were: Cmax was 1763 ng / mL, Tmax was 5.33 h, T1 / 2 was 3.34 h, AUC0-t was 22932 hr*ng / mL, AUC0-∞ was 23354 hr*ng / mL, MRT0-t was 6.75 h, MRT0-∞ was 7.10 h, and oral bioavailability was 116.1%. The results are shown in Table 8 below.
[0132] Table 8 Pharmacokinetic parameters of 4b in rats after intragastric administration (n=3)
[0133] Parameter Units NO.4 NO.5 No.6 Mean SD T1 / 2 hr 2.66 2.56 4.81 3.34 1.27 Tmax hr 4.00 6.00 6.00 5.33 1.15 Cmax ng / ml 1650 1460 2180 1763 373 <![CDATA[AUC 0-t ]]> hr*ng / ml 20275 19847 28674 22932 4977 <![CDATA[AUC 0-∞ ]]> hr*ng / ml 20337 19898 29826 23354 5610 <![CDATA[MRT 0-t ]]> hr 6.48 6.67 7.11 6.75 0.320 <![CDATA[MRT 0-∞ ]]> hr 6.55 6.72 8.03 7.10 0.808 F 101.1% 98.9% 148.3% 116.1% 0.279
[0134] According to the contents in Tables 4 to 8 above, it can be shown that the compounds provided by the present invention have good PDE8 inhibitory activity, PDE subtype selectivity, good liver microsomal stability and good pharmacokinetic properties and other drug-like properties, which fully demonstrates that the 3,8-disubstituted adenine derivative compounds in the present invention have good drug-like properties. It can be seen that the 3,8-disubstituted adenine derivatives described in the present invention have a broad application space as phosphodiesterase type 8 (PDE8) inhibitors and can be used for further drug research and development.
[0135] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof, characterized in that: in: The R1, R2 or R3 is C 1-6 Alkoxy, H, halogen, and C 1-6 At least one H on the alkoxy group is replaced by a halogen atom; R4 is selected from R5 is C 1-6 Alkyl, and C 1-6 At least one H on the alkyl group is replaced by a halogen atom, C 4-5 Heteroaryl, halogenated C 4-5 Heteroaryl, halogenated C6 aryl, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl or tetrahydropyran substitution.
2. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The C 1-6 The alkoxy group is selected from one of -OCHF2, -OCH2CHF2, and -OCH2CH2CF3.
3. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The C 1-6 Alkyl is selected from -CH2CHF2, One of them.
4. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The pharmaceutically acceptable salt is a salt obtained by reacting a compound of formula (I) with an acid, wherein the acid includes one or more of hydrochloric acid, hydrobromic acid, hydrofluoric acid, phosphoric acid, acetic acid, oxalic acid, sulfuric acid, methanesulfonic acid, salicylic acid, trifluoroacetic acid, trifluoromethanesulfonic acid, naphthalenesulfonic acid, maleic acid, fumaric acid, citric acid, tartaric acid, succinic acid, malic acid and glutamic acid.
5. A pharmaceutical composition comprising: a compound represented by formula (I) according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
6. Use of a substance X in the preparation of a phosphodiesterase type 8 inhibitor, characterized in that: The substance X is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, or a pharmaceutical composition according to claim 5.
7. Use of a substance X in the preparation of a drug, characterized in that: The substance X is a compound represented by formula (I) according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 5; the drug is a drug for treating and / or preventing diseases related to phosphodiesterase type 8.
